| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +2.79M | 80.4% | $8.00 | +$22.3M |
| Sells | 4 | -682K | 19.6% | $12.36 | -$8.43M |
| Net | -3 | +2.11M | 60.8% | +$13.9M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| GSK plc | 10%+ Owner | $134M | +$22.3M | +20% | Sep 27, 2024 |
| Ken Takanashi | Director, 10%+ Owner | $14.2M | Aug 12, 2024 | ||
| Paul Bolno | President and CEO, Director | $3.24M | -$4.74M | -59.4% | Mar 7, 2025 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $899K | Mar 4, 2025 | ||
| Gregory L. Verdine | Director | $775K | Mar 5, 2025 | ||
| Michael A. Panzara | Chief Medical Officer, Head of Therapeutics Discovery and Development | $546K | Jul 25, 2022 | ||
| Kyle Moran | Chief Financial Officer | $221K | -$154K | -41.1% | Feb 4, 2025 |
| Christian Henry | Director | $157K | -$103K | -39.5% | Mar 20, 2025 |
| Mark Corrigan | Director | $79.9K | Aug 12, 2024 | ||
| Heidi Wagner | Director | $79.9K | Aug 12, 2024 | ||
| Chris Francis | SVP, Corporate Development, Head of Emerging Areas | $62K | -$3.43M | -98.2% | Feb 4, 2025 |
| Ra Capital Management, L.P. | Director, 10%+ Owner | $40K | Aug 12, 2024 | ||
| Adrian Rawcliffe | Director | $40K | Aug 12, 2024 | ||
| Aik Na Tan | Director | $40K | Aug 12, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|